MASTOCHECK is an innovative cancer diagnostic software that analyzes the expression of three
breast cancer-specific protein biomarkers using mass spectrometry and
a proprietary AI-based algorithm, providing a highly accurate indication of early-stage breast cancer.
As a simple, radiation-free blood test, MASTOCHECK offers a convenient and non-invasive alternative to traditional imaging,
with high diagnostic performance even for women with dense breast tissue or implants.
Developed in collaboration with the Korea 21st Century Frontier Program, MASTOCHECK enhances early detection accuracy
by applying cutting-edge mass spectrometry technology and AI techniques to proteomic data,
enabling the reliable identification of early-stage breast cancer.
The test received regulatory approval from the Ministry of Food and Drug Safety in January 2019,
following its clinical validation in Stage 0, 1 and 2 breast cancer patients. In September 2019,
it was also awarded New Excellent Technology (NET) certification by the Ministry of Health and Welfare
Diagnoses early-stage
breast cancer (phases 0-2)
A simple test with
a small amount of blood
Safe in vitro diagnostic
medical device approved by
the Ministry of Food and
Drug Safety in South Korea
Visit a hospital /
clinic that provides
MASTOCHECK
Provide a small-volume
blood sample
Blood sample is sent to
a MASTOCHECK
testing center
Breast cancer specific
biomarkers are analyzed
by mass spectrometer
Biomarker values
are input into the proprietary
MASTOCHECK algorithm
Test result consultation
with a medical specialist
This product is a medical device. Please read and follow the precautions and instructions for use carefully.
The test results using this product alone cannot determine the diagnosis and treatment methods for stages 0, 1, and 2 of breast cancer.
For the diagnosis of stage 3 and 4 of breast cancer, additional clinical diagnostic tests are required.
